The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated survival follow-up for phase I study of abexinostat with pazopanib in patients with solid tumor malignancies.
 
Erica S Tsang
No Relationships to Disclose
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; Alessa Therapeutics; Alessa Therapeutics; Amgen; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon; Jubilant Pharmaceuticals; Merck; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Scott Thomas
No Relationships to Disclose
 
Mallika Sachdev Dhawan
Research Funding - Clovis Oncology; Genentech; JSI Pharma; Merck
 
Nela Pawlowska
No Relationships to Disclose
 
Imke Heleen Bartelink
No Relationships to Disclose
 
Jennifer A. Grabowsky
No Relationships to Disclose
 
Thierry Marie Jahan
No Relationships to Disclose
 
Thach-Giao Truong
No Relationships to Disclose
 
Charles J. Ryan
Honoraria - Bayer; Janssen Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Clovis Oncology (Inst); Dendreon; Myovant Sciences; Roivant
Research Funding - Clovis Oncology (Inst); Genzyme (Inst)
 
Pamela N. Munster
Leadership - Alessa Therapeutics; EpiAxis Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; OnKure
Honoraria - Alkermes; AstraZeneca/Merck; Athenex; GlaxoSmithKline; Olema Pharmaceuticals
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; BeiGene; Olema Pharmaceuticals; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Immune Design (Inst); Merck (Inst); Novartis (Inst); oncosec (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Tempest Therapeutics (Inst); Tesaro/GSK (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents